Juvaris BioTherapeutics' Vaccine Adjuvant, JVRS-100, Generates Superior T-Cell Mediated Immune Responses to Influenza in Clinical Trial

BURLINGAME, Calif.--(BUSINESS WIRE)--Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines and immunotherapeutics for infectious diseases and cancer, today announced clinical results demonstrating that its vaccine adjuvant, JVRS-100, when combined with a trivalent inactivated seasonal flu vaccine, generated robust T-cell mediated immune responses and antibody responses. Strong T-cell responses to influenza vaccine in humans have not been evidenced to date and remain an important goal for improved influenza vaccines particularly in elderly subjects. T-cell responses are critical to protection against influenza disease and recovery from infection.